Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.

Pérez-Salvia M, Aldaba E, Vara Y, Fabre M, Ferrer C, Masdeu C, Zubia A, Sebastian ES, Otaegui D, Llinàs-Arias P, Rosselló-Tortella M, Berdasco M, Moutinho C, Setien F, Villanueva A, González-Barca E, Muncunill J, Navarro JT, Piris MA, Cossio FP, Esteller M.

Haematologica. 2018 Nov;103(11):e537-e540. doi: 10.3324/haematol.2018.189241. Epub 2018 Jun 7. No abstract available.

2.

A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J.

J Clin Invest. 2013 Nov;123(11):4612-26.

3.

In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19.

4.
5.

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.

Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, Ott G, Rosenwald A.

Haematologica. 2018 Jan;103(1):116-125. doi: 10.3324/haematol.2017.177162. Epub 2017 Oct 27.

6.
7.

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.

Clin Cancer Res. 2015 Oct 15;21(20):4663-75. doi: 10.1158/1078-0432.CCR-14-3068. Epub 2015 Jun 26.

8.

AKT activation controls cell survival in response to HDAC6 inhibition.

Kaliszczak M, Trousil S, Ali T, Aboagye EO.

Cell Death Dis. 2016 Jun 30;7(6):e2286. doi: 10.1038/cddis.2016.180.

9.

Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.

Liu Z, Cai Y, Yang Y, Li A, Bi R, Wang L, Shen X, Wang W, Jia Y, Yu B, Cao B, Cui W, Wei P, Zhou X.

J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.

PMID:
29876933
10.

[Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].

Klener P Jr, Trněný M.

Klin Onkol. 2015;28 Suppl 3:3S80-6. Review. Czech.

PMID:
26489506
11.

HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis.

Liang M, Han X, Vadhan-Raj S, Nguyen M, Zhang YH, Fernandez M, Drakos E, Konoplev SN, Yin CC, Miranda RN, McDonnell TJ, Medeiros LJ, Bueso-Ramos CE.

Mod Pathol. 2010 Mar;23(3):381-91. doi: 10.1038/modpathol.2009.170. Epub 2010 Jan 8.

12.

B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.

Zhang W, Wang Y, Wang J, Dong F, Zhu M, Wan W, Li H, Wu F, Yan X, Ke X.

Int J Oncol. 2015;46(6):2562-72. doi: 10.3892/ijo.2015.2962. Epub 2015 Apr 9.

PMID:
25872657
13.

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D.

Haematologica. 2010 Nov;95(11):1865-72. doi: 10.3324/haematol.2009.019745. Epub 2010 Jul 27.

14.

The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.

Lu K, Chen N, Zhou XX, Ge XL, Feng LL, Li PP, Li XY, Geng LY, Wang X.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):292-8. doi: 10.1016/j.bbrc.2015.06.145. Epub 2015 Jun 24.

PMID:
26116769
15.

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.

Kaliszczak M, Trousil S, Åberg O, Perumal M, Nguyen QD, Aboagye EO.

Br J Cancer. 2013 Feb 5;108(2):342-50. doi: 10.1038/bjc.2012.576. Epub 2013 Jan 15.

16.

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.

Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z.

Haematologica. 2013 Sep;98(9):1458-66. doi: 10.3324/haematol.2012.071340. Epub 2013 Mar 18.

17.

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J.

Breast Cancer Res. 2015 Dec 8;17(1):149. doi: 10.1186/s13058-015-0658-0. Erratum in: Breast Cancer Res. 2017 Apr 19;19(1):49.

18.

The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.

Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.

Int J Cancer. 2018 Jan 1;142(1):202-213. doi: 10.1002/ijc.31044. Epub 2017 Oct 16.

19.

Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ.

Mol Cancer Ther. 2010 Jul;9(7):2026-36. doi: 10.1158/1535-7163.MCT-10-0238. Epub 2010 Jul 6.

20.

Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma.

Henson SE, Morford T, Stein MP, Wall R, Malone CS.

Acta Histochem. 2011 Nov;113(7):729-42. doi: 10.1016/j.acthis.2010.11.001. Epub 2010 Dec 9.

Supplemental Content

Support Center